Journal Home
Search for

Volume 108, Issue 3, Pages 282-288 (March 2010)


View previous. 29 of 34 View next.

Expanding uterotonic protection following childbirth through community-based distribution of misoprostol: Operations research study in Nepal

Swaraj Rajbhandaria, Stephen HodginsbCorresponding Author Informationemail address, Harshad Sanghvic, Robert McPhersond, Yasho V. Pradhane, Abdullah H. Baquid, Misoprostol Study Group1

published online 25 December 2009.

Abstract 

Objective

To determine feasibility of community-based distribution of misoprostol for preventing postpartum hemorrhage (PPH) to pregnant woman through community volunteers working under government health services.

Methods

Implemented in one district in Nepal. The primary measure of performance was uterotonic protection after childbirth, measured using pre- and postintervention surveys (28 clusters, each with 30 households). Maternal deaths were ascertained through systematic health facility and community-based surveillance; causes of death were assigned based on verbal autopsy.

Results

Of 840 postintervention survey respondents, 73.2% received misoprostol. The standardized proportion of vaginal deliveries protected by a uterotonic rose from 11.6% to 74.2%. Those experiencing the largest gains were the poor, the illiterate, and those living in remote areas.

Conclusion

Community-based distribution of misoprostol for PPH prevention can be successfully implemented under government health services in a low-resource, geographically challenging setting, resulting in much increased population-level protection against PPH, with particularly large gains among the disadvantaged.

a Options/Cambodia

b Nepal Family Health Program, JSI R&T, Kathmandu, Nepal

c JHPIEGO, Baltimore, MD, USA

d Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

e Ministry of Health and Population, Government of Nepal, Kathmandu, Nepal

Corresponding Author InformationCorresponding author.

1 Other members of the Misoprostol Study Group are given at the end of the manuscript.

PII: S0020-7292(09)00644-4

doi:10.1016/j.ijgo.2009.11.006


View previous. 29 of 34 View next.